Consider Minocycline: A Familiar Drug for Some Unfamiliar Pathogens

Minocycline demonstrated reliable activity in vitro against several uncommon gram-negative pathogens.

The growing number of immunocompromised patients has increased the likelihood of serious infections with unusual gram-negative bacteria (e.g., Achromobacter spp., Burkholderia cepacia species complex, Aeromonas spp., Chryseobacterium spp., Alcaligenes faecalis, Stenotrophomonas maltophilia). As these bacteria are not often encountered in FDA approval and registrational studies of newer antibiotics, their antimicrobial susceptibilities remain poorly characterized.

Researchers examined the activity of minocycline and other antibiotics against 3856 isolates of uncommon gram-negative bacteria collected from hospitalized patients between 2014 and 2019. Susceptibility was determined by Clinical and Laboratory Standards Institute criteria if availa…

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases